Allergan Plans Job Cuts As Ackman Pushes For Vote

Jul 21 2014 | 1:42pm ET

Allergan Inc. and Pershing Square Capital Management are making their pitches for their opposing views on a proposed $53 billion deal for the Botox maker.

Allergan today announced stronger-than-expected second-quarter profits and boosted its earnings outlook for the rest of the year. It also announced plans to cut 13% of its workforce, a move that will save $475 million next year.

Allergan is seeking to fend off the Pershing Square-backed offer from Valeant Pharmaceuticals International.

Meanwhile, Pershing Square’s William Ackman met with Institutional Shareholder Services last week to urge the proxy adviser to back it and Valeant’s call for a special shareholder meeting to vote his slate of candidates to take control of the company’s board. At the meeting, he blasted Allergan for what he called anti-shareholder bylaws.

Ackman reiterated that criticism at a hedge fund conference on Wednesday, calling Allergan’s requirements for the special meeting “unbelievably burdensome”—and that he’s seeking support of 45% of shareholders, rather than the 25% needed.

Still, Ackman called his joint bid with Valeant a “happy,” rather than hostile, one.

As Ackman and Allergan press the flesh, they can yank one name from their Rolodexes and add another: Mutual fund giant Capital Research and Management Co., Allergan’s largest shareholder until Pershing Square took its nearly 10% stake earlier this year, has sold its entire holdings of the pharmaceutical company. The Los Angeles-based firm had owned a 6.3% stake.

CRM sold its position after a meeting with Allergan CEO David Pyott.

Meanwhile, another hedge fund has joined Pershing Square and Paulson & Co. in buying in to Allergan: Samlyn Capital, led by SAC Capital Advisors veteran Robert Pohly, has boosted its stake to $150 million. The hedge fund has owned a small stake in the company since last summer, but recently made the company one of its five largest long bets.

Unlike Pershing Square and Paulson, which both support the Valeant deal, Samlyn has yet to take sides. It’s stake is much smaller than either of the other hedge funds, amounting to less than half a percent. Paulson’s stake is 2% and Pershing Square owns 9.7%.


In Depth

Q&A: Neil Azous Talks Global Macro Investing

Nov 24 2014 | 12:41pm ET

Neil Azous is the founder and managing member of Rareview Macro, an advisory firm...

Lifestyle

Griffin Selling Chicago Apartment

Nov 26 2014 | 11:40am ET

Citadel Investment Group’s Kenneth Griffin is making clear to his estranged wife...

Guest Contributor

Why The Big Money Is Going To Europe

Nov 14 2014 | 6:03am ET

Peer-to-peer lending was invented with the individual investor in mind. But despite...

 

Sponsored Content

    For Hedge Funds, Mastering Data Is Key To Success

    Nov 4 2014 | 9:45am ET

    Data management is important to every business, but for hedge funds, it is critical. FINalternatives recently asked Peter Sanchez, CEO of Northern Trust Hedge Fund Services, how fund managers can deal with the demands of managing data while at the same time remain transparent and abide by operational best practices. Read more…

Editor's Note

    Guidelines for Guest Articles

    Oct 22 2014 | 9:46am ET

    We are always looking for guest articles from hedge fund managers and buy-side firms.

    If you are interested in submitting a contributed piece for possible publication on FINalternatives, please take a look at the specs. Read more…

 

Futures Magazine

November 2014 Cover

Building a better market

Reg NMS created a huge bifurcation in equity markets and while much of what has followed has been positive, in terms of lower fees and greater liquidity, many traders would like to see the market come...

The Alpha Pages

TAP July/August 2014 Cover

The Alpha Pages Interview: Senator Rand Paul

Senator Paul sat down in the debut series of the Alpha Pages Interview to discuss the broken tax code, regulation surrounding Bitcoin, and his plans for the 2016 Presidential election.